25 XP   0   0   10

Jubilant Pharmova Limited
Buy, Hold or Sell?

Let's analyse Jubilant Pharmova Limited together

PenkeI guess you are interested in Jubilant Pharmova Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Jubilant Pharmova Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Jubilant Pharmova Limited

I send you an email if I find something interesting about Jubilant Pharmova Limited.

Quick analysis of Jubilant Pharmova Limited (30 sec.)










What can you expect buying and holding a share of Jubilant Pharmova Limited? (30 sec.)

How much money do you get?

How much money do you get?
INR0.24
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
INR338.79
Expected worth in 1 year
INR357.96
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
INR39.29
Return On Investment
6.9%

For what price can you sell your share?

Current Price per Share
INR569.90
Expected price per share
INR485.10 - INR627.45
How sure are you?
50%

1. Valuation of Jubilant Pharmova Limited (5 min.)




Live pricePrice per Share (EOD)

INR569.90

Intrinsic Value Per Share

INR-661.94 - INR138.93

Total Value Per Share

INR-323.15 - INR477.72

2. Growth of Jubilant Pharmova Limited (5 min.)




Is Jubilant Pharmova Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$647m$637.9m$9m1.4%

How much money is Jubilant Pharmova Limited making?

Current yearPrevious yearGrowGrow %
Making money-$7.3m$49.6m-$56.9m-778.8%
Net Profit Margin-1.0%6.8%--

How much money comes from the company's main activities?

3. Financial Health of Jubilant Pharmova Limited (5 min.)




What can you expect buying and holding a share of Jubilant Pharmova Limited? (5 min.)

Welcome investor! Jubilant Pharmova Limited's management wants to use your money to grow the business. In return you get a share of Jubilant Pharmova Limited.

What can you expect buying and holding a share of Jubilant Pharmova Limited?

First you should know what it really means to hold a share of Jubilant Pharmova Limited. And how you can make/lose money.

Speculation

The Price per Share of Jubilant Pharmova Limited is INR569.90. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Jubilant Pharmova Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Jubilant Pharmova Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is INR338.79. Based on the TTM, the Book Value Change Per Share is INR4.79 per quarter. Based on the YOY, the Book Value Change Per Share is INR36.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is INR5.03 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Jubilant Pharmova Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 INR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per ShareINR% of Price per Share
Usd Eps-0.050.0%-0.050.0%0.310.1%0.400.1%0.330.1%
Usd Book Value Change Per Share0.060.0%0.060.0%0.440.1%0.200.0%0.210.0%
Usd Dividend Per Share0.060.0%0.060.0%0.060.0%0.060.0%0.050.0%
Usd Total Gains Per Share0.120.0%0.120.0%0.500.1%0.260.0%0.260.0%
Usd Price Per Share3.35-3.35-4.65-5.14-5.03-
Price to Earnings Ratio-72.94--72.94-14.91--5.06-0.82-
Price-to-Total Gains Ratio28.45-28.45-9.38-8.02-8.91-
Price to Book Ratio0.82-0.82-1.16-1.36-1.65-
Price-to-Total Gains Ratio28.45-28.45-9.38-8.02-8.91-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.8388
Number of shares146
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.060.06
Usd Book Value Change Per Share0.060.20
Usd Total Gains Per Share0.120.26
Gains per Quarter (146 shares)17.2137.55
Gains per Year (146 shares)68.84150.21
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
135345933118140
2716712865235290
310610119798353440
4141134266130471590
5176168335163589740
6212202404195706890
72472354732288241040
82822695422609421190
931730261129310591340
1035333668032511771490

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%18.02.00.090.0%
Book Value Change Per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%17.03.00.085.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%20.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%4.01.00.080.0%8.02.00.080.0%17.03.00.085.0%

Fundamentals of Jubilant Pharmova Limited

About Jubilant Pharmova Limited

Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.

Fundamental data was last updated by Penke on 2024-03-23 12:31:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Jubilant Pharmova Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Jubilant Pharmova Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Jubilant Pharmova Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -1.0% means that ₹-0.01 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Jubilant Pharmova Limited:

  • The MRQ is -1.0%. The company is not making a profit/loss.
  • The TTM is -1.0%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ-1.0%TTM-1.0%0.0%
TTM-1.0%YOY6.8%-7.8%
TTM-1.0%5Y7.3%-8.2%
5Y7.3%10Y6.3%+0.9%
1.1.2. Return on Assets

Shows how efficient Jubilant Pharmova Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Jubilant Pharmova Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.5% Return on Assets means that Jubilant Pharmova Limited generated ₹-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Jubilant Pharmova Limited:

  • The MRQ is -0.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -0.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM-0.5%0.0%
TTM-0.5%YOY4.1%-4.7%
TTM-0.5%5Y5.0%-5.6%
5Y5.0%10Y4.4%+0.7%
1.1.3. Return on Equity

Shows how efficient Jubilant Pharmova Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Jubilant Pharmova Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.1% Return on Equity means Jubilant Pharmova Limited generated ₹-0.01 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Jubilant Pharmova Limited:

  • The MRQ is -1.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.1%TTM-1.1%0.0%
TTM-1.1%YOY7.8%-8.9%
TTM-1.1%5Y10.5%-11.6%
5Y10.5%10Y10.1%+0.3%

1.2. Operating Efficiency of Jubilant Pharmova Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Jubilant Pharmova Limited is operating .

  • Measures how much profit Jubilant Pharmova Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Jubilant Pharmova Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 4.4% means the company generated ₹0.04  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Jubilant Pharmova Limited:

  • The MRQ is 4.4%. The company is operating less efficient.
  • The TTM is 4.4%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ4.4%TTM4.4%0.0%
TTM4.4%YOY12.7%-8.4%
TTM4.4%5Y13.5%-9.1%
5Y13.5%10Y13.2%+0.4%
1.2.2. Operating Ratio

Measures how efficient Jubilant Pharmova Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.96 means that the operating costs are ₹0.96 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Jubilant Pharmova Limited:

  • The MRQ is 0.964. The company is less efficient in keeping operating costs low.
  • The TTM is 0.964. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.964TTM0.9640.000
TTM0.964YOY0.864+0.100
TTM0.9645Y0.864+0.100
5Y0.86410Y0.862+0.002

1.3. Liquidity of Jubilant Pharmova Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Jubilant Pharmova Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.12 means the company has ₹2.12 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Jubilant Pharmova Limited:

  • The MRQ is 2.123. The company is able to pay all its short-term debts. +1
  • The TTM is 2.123. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.123TTM2.1230.000
TTM2.123YOY2.205-0.082
TTM2.1235Y2.252-0.129
5Y2.25210Y1.779+0.473
1.3.2. Quick Ratio

Measures if Jubilant Pharmova Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Jubilant Pharmova Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.27 means the company can pay off ₹1.27 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Jubilant Pharmova Limited:

  • The MRQ is 1.268. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.268. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.268TTM1.2680.000
TTM1.268YOY1.418-0.150
TTM1.2685Y1.517-0.250
5Y1.51710Y0.917+0.600

1.4. Solvency of Jubilant Pharmova Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Jubilant Pharmova Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Jubilant Pharmova Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.52 means that Jubilant Pharmova Limited assets are financed with 51.7% credit (debt) and the remaining percentage (100% - 51.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Jubilant Pharmova Limited:

  • The MRQ is 0.517. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.517. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.517TTM0.5170.000
TTM0.517YOY0.468+0.049
TTM0.5175Y0.5170.000
5Y0.51710Y0.587-0.069
1.4.2. Debt to Equity Ratio

Measures if Jubilant Pharmova Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Jubilant Pharmova Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 106.8% means that company has ₹1.07 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Jubilant Pharmova Limited:

  • The MRQ is 1.068. The company is able to pay all its debts with equity. +1
  • The TTM is 1.068. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.068TTM1.0680.000
TTM1.068YOY0.879+0.189
TTM1.0685Y1.089-0.022
5Y1.08910Y1.536-0.447

2. Market Valuation of Jubilant Pharmova Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Jubilant Pharmova Limited generates.

  • Above 15 is considered overpriced but always compare Jubilant Pharmova Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -72.94 means the investor is paying ₹-72.94 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Jubilant Pharmova Limited:

  • The EOD is -148.734. Based on the earnings, the company is expensive. -2
  • The MRQ is -72.945. Based on the earnings, the company is expensive. -2
  • The TTM is -72.945. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-148.734MRQ-72.945-75.790
MRQ-72.945TTM-72.9450.000
TTM-72.945YOY14.907-87.851
TTM-72.9455Y-5.059-67.886
5Y-5.05910Y0.823-5.882
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Jubilant Pharmova Limited:

  • The EOD is -58.979. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -28.926. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -28.926. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-58.979MRQ-28.926-30.054
MRQ-28.926TTM-28.9260.000
TTM-28.926YOY25.975-54.900
TTM-28.9265Y5.778-34.704
5Y5.77810Y7.388-1.610
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Jubilant Pharmova Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.82 means the investor is paying ₹0.82 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Jubilant Pharmova Limited:

  • The EOD is 1.682. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.825. Based on the equity, the company is cheap. +2
  • The TTM is 0.825. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.682MRQ0.825+0.857
MRQ0.825TTM0.8250.000
TTM0.825YOY1.161-0.336
TTM0.8255Y1.359-0.534
5Y1.35910Y1.649-0.290
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Jubilant Pharmova Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.7934.7930%36.290-87%16.796-71%17.519-73%
Book Value Per Share--338.792338.7920%333.999+1%325.205+4%260.686+30%
Current Ratio--2.1232.1230%2.205-4%2.252-6%1.779+19%
Debt To Asset Ratio--0.5170.5170%0.468+10%0.5170%0.587-12%
Debt To Equity Ratio--1.0681.0680%0.879+21%1.089-2%1.536-30%
Dividend Per Share--5.0315.0310%5.029+0%4.639+8%4.068+24%
Eps---3.832-3.8320%26.005-115%33.466-111%27.458-114%
Free Cash Flow Per Share---9.663-9.6630%14.924-165%34.879-128%38.060-125%
Free Cash Flow To Equity Per Share---19.508-19.5080%12.876-252%6.149-417%2.562-862%
Gross Profit Margin--3.5033.5030%0.623+462%1.262+178%1.124+212%
Intrinsic Value_10Y_max--138.926--------
Intrinsic Value_10Y_min---661.941--------
Intrinsic Value_1Y_max--32.930--------
Intrinsic Value_1Y_min--4.304--------
Intrinsic Value_3Y_max--84.454--------
Intrinsic Value_3Y_min---48.171--------
Intrinsic Value_5Y_max--118.514--------
Intrinsic Value_5Y_min---167.209--------
Market Cap90244239459.200+51%44481735473.50044481735473.5000%61703800712.350-28%68163540948.138-35%66570899088.529-33%
Net Profit Margin---0.010-0.0100%0.068-114%0.073-114%0.063-115%
Operating Margin--0.0440.0440%0.127-66%0.135-68%0.132-67%
Operating Ratio--0.9640.9640%0.864+12%0.864+12%0.862+12%
Pb Ratio1.682+51%0.8250.8250%1.161-29%1.359-39%1.649-50%
Pe Ratio-148.734-104%-72.945-72.9450%14.907-589%-5.059-93%0.823-8961%
Price Per Share569.900+51%279.500279.5000%387.650-28%428.730-35%419.166-33%
Price To Free Cash Flow Ratio-58.979-104%-28.926-28.9260%25.975-211%5.778-601%7.388-492%
Price To Total Gains Ratio58.016+51%28.45328.4530%9.382+203%8.022+255%8.911+219%
Quick Ratio--1.2681.2680%1.418-11%1.517-16%0.917+38%
Return On Assets---0.005-0.0050%0.041-113%0.050-111%0.044-113%
Return On Equity---0.011-0.0110%0.078-115%0.105-111%0.101-111%
Total Gains Per Share--9.8239.8230%41.319-76%21.434-54%21.587-54%
Usd Book Value--647014800.000647014800.0000%637968000.000+1%620702520.000+4%497302824.000+30%
Usd Book Value Change Per Share--0.0580.0580%0.435-87%0.202-71%0.210-73%
Usd Book Value Per Share--4.0664.0660%4.008+1%3.902+4%3.128+30%
Usd Dividend Per Share--0.0600.0600%0.060+0%0.056+8%0.049+24%
Usd Eps---0.046-0.0460%0.312-115%0.402-111%0.330-114%
Usd Free Cash Flow---18453600.000-18453600.0000%28506240.000-165%66597864.000-128%72597672.000-125%
Usd Free Cash Flow Per Share---0.116-0.1160%0.179-165%0.419-128%0.457-125%
Usd Free Cash Flow To Equity Per Share---0.234-0.2340%0.155-252%0.074-417%0.031-862%
Usd Market Cap1082930873.510+51%533780825.682533780825.6820%740445608.548-28%817962491.378-35%798850789.062-33%
Usd Price Per Share6.839+51%3.3543.3540%4.652-28%5.145-35%5.030-33%
Usd Profit---7317600.000-7317600.0000%49672320.000-115%63876648.000-111%52352964.000-114%
Usd Revenue--746316000.000746316000.0000%727099800.000+3%869183184.000-14%799250616.000-7%
Usd Total Gains Per Share--0.1180.1180%0.496-76%0.257-54%0.259-54%
 EOD+6 -2MRQTTM+0 -0YOY+12 -245Y+13 -2310Y+15 -21

3.2. Fundamental Score

Let's check the fundamental score of Jubilant Pharmova Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-148.734
Price to Book Ratio (EOD)Between0-11.682
Net Profit Margin (MRQ)Greater than0-0.010
Operating Margin (MRQ)Greater than00.044
Quick Ratio (MRQ)Greater than11.268
Current Ratio (MRQ)Greater than12.123
Debt to Asset Ratio (MRQ)Less than10.517
Debt to Equity Ratio (MRQ)Less than11.068
Return on Equity (MRQ)Greater than0.15-0.011
Return on Assets (MRQ)Greater than0.05-0.005
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Jubilant Pharmova Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.492
Ma 20Greater thanMa 50570.910
Ma 50Greater thanMa 100573.982
Ma 100Greater thanMa 200531.027
OpenGreater thanClose572.150
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2019-03-312020-03-312021-03-312022-03-312023-03-31
Net Income  5,744,5603,237,9008,982,460-623,7708,358,690-4,219,3304,139,360-4,749,160-609,800
Net Income from Continuing Operations  5,770,0803,212,3508,982,430-3,243,8305,738,600-1,608,4004,130,200-4,779,000-648,800
Net Income Applicable to Common Shares  5,744,5603,237,9008,982,460-623,7708,358,690-4,219,3304,139,360-4,749,160-609,800



Latest Balance Sheet

Balance Sheet of 2023-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets111,566,500
Total Liabilities57,648,600
Total Stockholder Equity53,992,800
 As reported
Total Liabilities 57,648,600
Total Stockholder Equity+ 53,992,800
Total Assets = 111,566,500

Assets

Total Assets111,566,500
Total Current Assets37,624,000
Long-term Assets73,942,500
Total Current Assets
Cash And Cash Equivalents 10,139,200
Short-term Investments 1,294,200
Net Receivables 9,739,200
Inventory 13,805,300
Other Current Assets 2,646,100
Total Current Assets  (as reported)37,624,000
Total Current Assets  (calculated)37,624,000
+/-0
Long-term Assets
Property Plant Equipment 33,651,200
Goodwill 24,285,900
Intangible Assets 9,510,400
Other Assets 3,930,810
Long-term Assets  (as reported)73,942,500
Long-term Assets  (calculated)71,378,310
+/- 2,564,190

Liabilities & Shareholders' Equity

Total Current Liabilities17,724,000
Long-term Liabilities39,924,600
Total Stockholder Equity53,992,800
Total Current Liabilities
Short-term Debt 3,531,200
Short Long Term Debt 2,997,200
Accounts payable 8,213,200
Other Current Liabilities 1,217,800
Total Current Liabilities  (as reported)17,724,000
Total Current Liabilities  (calculated)15,959,400
+/- 1,764,600
Long-term Liabilities
Long term Debt 31,103,600
Capital Lease Obligations Min Short Term Debt-864,400
Other Liabilities 6,688,130
Long-term Liabilities Other 2,685,100
Long-term Liabilities  (as reported)39,924,600
Long-term Liabilities  (calculated)39,612,430
+/- 312,170
Total Stockholder Equity
Common Stock159,100
Retained Earnings 45,367,310
Accumulated Other Comprehensive Income 8,514,260
Other Stockholders Equity -47,870
Total Stockholder Equity (as reported)53,992,800
Total Stockholder Equity (calculated)53,992,800
+/-0
Other
Capital Stock159,100
Cash and Short Term Investments 11,433,400
Common Stock Shares Outstanding 159,148
Current Deferred Revenue4,761,800
Liabilities and Stockholders Equity 111,566,500
Net Debt 26,628,400
Net Invested Capital 88,093,600
Net Tangible Assets 20,196,520
Net Working Capital 19,900,000
Property Plant and Equipment Gross 33,651,200
Short Long Term Debt Total 36,767,600



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-312004-03-31
> Total Assets 
8,696,100
12,627,690
20,514,790
32,432,190
42,093,920
66,035,960
68,245,160
75,638,540
78,459,190
84,319,670
88,605,560
86,322,150
89,470,240
90,406,470
96,176,180
114,685,050
125,216,520
89,181,100
99,908,670
111,566,500
111,566,50099,908,67089,181,100125,216,520114,685,05096,176,18090,406,47089,470,24086,322,15088,605,56084,319,67078,459,19075,638,54068,245,16066,035,96042,093,92032,432,19020,514,79012,627,6908,696,100
   > Total Current Assets 
3,731,430
5,298,380
8,949,100
17,654,340
17,397,850
19,671,780
22,315,080
28,227,890
23,438,080
26,571,250
29,280,300
27,279,290
29,013,210
29,481,210
31,897,570
45,847,990
50,383,490
29,525,010
35,091,920
37,624,000
37,624,00035,091,92029,525,01050,383,49045,847,99031,897,57029,481,21029,013,21027,279,29029,280,30026,571,25023,438,08028,227,89022,315,08019,671,78017,397,85017,654,3408,949,1005,298,3803,731,430
       Cash And Cash Equivalents 
227,450
375,740
1,389,570
8,749,110
5,237,680
3,816,640
5,036,740
10,456,940
2,671,860
3,538,990
4,767,140
3,908,750
3,404,300
4,518,870
2,392,000
9,999,240
12,253,170
4,979,350
9,802,630
10,139,200
10,139,2009,802,6304,979,35012,253,1709,999,2402,392,0004,518,8703,404,3003,908,7504,767,1403,538,9902,671,86010,456,9405,036,7403,816,6405,237,6808,749,1101,389,570375,740227,450
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
144,880
294,560
3,770,340
1,873,930
1,874,720
53,530
1,294,200
1,294,20053,5301,874,7201,873,9303,770,340294,560144,8800000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,233,540
17,862,560
17,776,700
11,373,910
12,654,130
9,739,200
9,739,20012,654,13011,373,91017,776,70017,862,56014,233,54000000000000000
       Inventory 
1,314,280
1,937,460
3,116,890
3,532,430
4,349,670
5,956,100
6,909,510
6,912,780
10,202,220
11,149,140
13,414,170
12,353,250
12,160,620
12,203,990
13,913,880
14,173,940
18,453,790
11,293,810
12,548,690
13,805,300
13,805,30012,548,69011,293,81018,453,79014,173,94013,913,88012,203,99012,160,62012,353,25013,414,17011,149,14010,202,2206,912,7806,909,5105,956,1004,349,6703,532,4303,116,8901,937,4601,314,280
       Other Current Assets 
2,189,700
2,985,180
4,442,640
5,372,800
7,810,500
9,899,040
10,368,830
10,858,170
10,564,000
11,883,120
11,098,990
11,017,290
13,448,290
12,613,470
15,297,130
41,910
25,900
3,220
32,940
2,646,100
2,646,10032,9403,22025,90041,91015,297,13012,613,47013,448,29011,017,29011,098,99011,883,12010,564,00010,858,17010,368,8309,899,0407,810,5005,372,8004,442,6402,985,1802,189,700
   > Long-term Assets 
4,964,670
7,329,310
11,565,690
14,777,850
24,696,070
46,364,180
45,930,080
47,410,650
55,021,110
57,748,420
59,325,260
59,042,860
60,457,030
60,925,260
64,278,610
68,837,060
74,833,030
59,656,090
64,816,750
73,942,500
73,942,50064,816,75059,656,09074,833,03068,837,06064,278,61060,925,26060,457,03059,042,86059,325,26057,748,42055,021,11047,410,65045,930,08046,364,18024,696,07014,777,85011,565,6907,329,3104,964,670
       Property Plant Equipment 
4,679,820
6,244,040
8,637,140
11,437,020
17,235,190
26,049,290
26,722,160
29,911,950
31,159,070
32,683,300
32,315,740
31,856,860
32,467,470
33,146,890
34,926,100
38,878,160
42,874,820
25,751,930
27,910,990
33,651,200
33,651,20027,910,99025,751,93042,874,82038,878,16034,926,10033,146,89032,467,47031,856,86032,315,74032,683,30031,159,07029,911,95026,722,16026,049,29017,235,19011,437,0208,637,1406,244,0404,679,820
       Goodwill 
0
0
0
2,679,220
6,297,730
15,844,610
0
15,837,860
0
16,765,590
17,780,140
17,324,680
18,311,040
17,622,270
18,876,980
19,589,360
20,894,610
21,299,620
22,427,540
24,285,900
24,285,90022,427,54021,299,62020,894,61019,589,36018,876,98017,622,27018,311,04017,324,68017,780,14016,765,590015,837,860015,844,6106,297,7302,679,220000
       Intangible Assets 
155,160
201,570
0
315,640
170,840
158,610
16,523,040
938,300
20,298,160
4,594,620
5,615,860
5,897,790
6,071,150
7,135,920
6,912,190
7,030,520
7,314,170
8,005,860
9,263,230
9,510,400
9,510,4009,263,2308,005,8607,314,1707,030,5206,912,1907,135,9206,071,1505,897,7905,615,8604,594,62020,298,160938,30016,523,040158,610170,840315,6400201,570155,160
       Long-term Assets Other 
97,930
830,390
2,928,550
283,650
740,190
3,145,510
2,684,880
327,520
3,461,040
3,204,080
3,613,520
3,963,530
3,607,370
718,940
1,018,220
4,462,830
943,390
510,710
1,216,280
1,656,370
1,656,3701,216,280510,710943,3904,462,8301,018,220718,9403,607,3703,963,5303,613,5203,204,0803,461,040327,5202,684,8803,145,510740,190283,6502,928,550830,39097,930
> Total Liabilities 
6,598,110
7,582,780
12,106,700
23,370,840
29,531,950
53,360,500
45,852,620
53,497,770
54,471,940
58,260,750
60,761,070
61,786,990
60,374,550
56,438,920
55,826,100
66,594,890
69,177,700
41,765,930
46,744,670
57,648,600
57,648,60046,744,67041,765,93069,177,70066,594,89055,826,10056,438,92060,374,55061,786,99060,761,07058,260,75054,471,94053,497,77045,852,62053,360,50029,531,95023,370,84012,106,7007,582,7806,598,110
   > Total Current Liabilities 
1,614,680
2,952,840
3,844,330
5,248,120
6,679,090
11,943,090
12,201,130
12,145,550
22,127,860
27,944,200
38,911,570
21,425,500
25,144,830
16,759,370
20,046,940
20,897,290
26,190,130
10,488,330
15,916,010
17,724,000
17,724,00015,916,01010,488,33026,190,13020,897,29020,046,94016,759,37025,144,83021,425,50038,911,57027,944,20022,127,86012,145,55012,201,13011,943,0906,679,0905,248,1203,844,3302,952,8401,614,680
       Short-term Debt 
0
0
0
0
0
0
0
0
7,670,670
13,233,860
26,783,990
11,018,320
14,727,360
5,402,520
4,210,810
5,975,380
9,325,780
701,350
5,155,670
3,531,200
3,531,2005,155,670701,3509,325,7805,975,3804,210,8105,402,52014,727,36011,018,32026,783,99013,233,8607,670,67000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,115,500
5,881,660
8,885,300
200,000
4,633,700
2,997,200
2,997,2004,633,700200,0008,885,3005,881,6604,115,50000000000000000
       Accounts payable 
741,810
1,406,310
0
2,545,930
3,066,470
5,360,760
5,018,400
4,878,090
8,369,830
10,562,230
7,181,370
6,991,560
5,996,410
7,494,900
11,361,610
10,201,270
10,902,690
5,204,840
5,677,400
8,213,200
8,213,2005,677,4005,204,84010,902,69010,201,27011,361,6107,494,9005,996,4106,991,5607,181,37010,562,2308,369,8304,878,0905,018,4005,360,7603,066,4702,545,93001,406,310741,810
       Other Current Liabilities 
872,870
1,546,530
3,844,330
2,702,190
3,612,620
6,582,330
7,182,730
7,267,460
6,087,360
4,148,110
4,946,210
3,415,620
4,421,060
3,238,400
3,713,430
4,444,890
15,287,440
1,009,500
1,518,600
1,217,800
1,217,8001,518,6001,009,50015,287,4404,444,8903,713,4303,238,4004,421,0603,415,6204,946,2104,148,1106,087,3607,267,4607,182,7306,582,3303,612,6202,702,1903,844,3301,546,530872,870
   > Long-term Liabilities 
4,983,430
4,629,940
8,262,370
18,122,720
22,852,860
41,417,410
33,651,490
41,352,220
32,344,080
30,316,550
21,849,500
40,361,490
35,229,720
39,679,550
35,779,160
45,697,600
42,987,570
31,277,600
30,828,660
39,924,600
39,924,60030,828,66031,277,60042,987,57045,697,60035,779,16039,679,55035,229,72040,361,49021,849,50030,316,55032,344,08041,352,22033,651,49041,417,41022,852,86018,122,7208,262,3704,629,9404,983,430
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,301,080
3,268,700
4,229,460
3,683,320
4,064,310
6,688,130
6,688,1304,064,3103,683,3204,229,4603,268,7005,301,08000000000000000
> Total Stockholder Equity
2,058,900
4,994,410
8,257,200
8,887,230
12,348,060
12,355,940
22,013,360
21,722,660
23,297,730
24,943,510
26,265,140
24,535,160
29,095,690
34,360,430
40,865,300
48,089,170
56,038,820
47,414,860
53,185,630
53,992,800
53,992,80053,185,63047,414,86056,038,82048,089,17040,865,30034,360,43029,095,69024,535,16026,265,14024,943,51023,297,73021,722,66022,013,36012,355,94012,348,0608,887,2308,257,2004,994,4102,058,900
   Common Stock
117,320
129,580
142,460
143,760
146,960
147,560
158,800
159,300
159,300
159,300
154,460
159,300
159,300
155,750
155,790
159,290
159,300
159,190
159,190
159,100
159,100159,190159,190159,300159,290155,790155,750159,300159,300154,460159,300159,300159,300158,800147,560146,960143,760142,460129,580117,320
   Retained Earnings 
1,048,350
1,702,690
2,390,690
3,960,050
6,697,990
7,768,460
9,492,270
9,267,660
8,806,180
9,644,300
10,246,430
8,912,180
12,652,610
20,983,790
26,396,920
31,026,410
38,448,170
43,177,110
46,850,170
45,367,310
45,367,31046,850,17043,177,11038,448,17031,026,41026,396,92020,983,79012,652,6108,912,18010,246,4309,644,3008,806,1809,267,6609,492,2707,768,4606,697,9903,960,0502,390,6901,702,6901,048,350
   Capital Surplus 00000000000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 
893,230
3,162,140
5,724,050
4,783,420
5,503,110
4,439,920
12,362,290
12,295,700
14,332,250
15,139,910
15,864,250
15,463,680
16,283,780
13,220,890
14,312,590
16,903,470
5,885,720
13,320
-48,000
-47,870
-47,870-48,00013,3205,885,72016,903,47014,312,59013,220,89016,283,78015,463,68015,864,25015,139,91014,332,25012,295,70012,362,2904,439,9205,503,1104,783,4205,724,0503,162,140893,230



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2023-03-31)

Gross Profit (+$)
totalRevenue62,193,000
Cost of Revenue-18,779,300
Gross Profit43,413,70043,413,700
 
Operating Income (+$)
Gross Profit43,413,700
Operating Expense-41,191,500
Operating Income3,748,7702,222,200
 
Operating Expense (+$)
Research Development0
Selling General Administrative2,230,780
Selling And Marketing Expenses1,526,510
Operating Expense41,191,5003,757,290
 
Net Interest Income (+$)
Interest Income98,280
Interest Expense-1,882,000
Other Finance Cost-98,280
Net Interest Income-1,882,000
 
Pretax Income (+$)
Operating Income3,748,770
Net Interest Income-1,882,000
Other Non-Operating Income Expenses0
Income Before Tax (EBT)277,8007,219,730
EBIT - interestExpense = 846,000
316,800
1,272,200
Interest Expense1,882,000
Earnings Before Interest and Taxes (EBIT)2,728,0002,159,800
Earnings Before Interest and Taxes (EBITDA)8,268,300
 
After tax Income (+$)
Income Before Tax277,800
Tax Provision-926,600
Net Income From Continuing Ops-648,800-648,800
Net Income-609,800
Net Income Applicable To Common Shares-609,800
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses59,970,800
Total Other Income/Expenses Net-3,470,9601,882,000
 

Technical Analysis of Jubilant Pharmova Limited
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Jubilant Pharmova Limited. The general trend of Jubilant Pharmova Limited is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Jubilant Pharmova Limited's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Jubilant Pharmova Limited.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 612.00 < 627.45.

The bearish price targets are: 538.05 > 532.15 > 485.10.

Tweet this
Jubilant Pharmova Limited Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Jubilant Pharmova Limited. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Jubilant Pharmova Limited Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Jubilant Pharmova Limited. The current macd is -1.70117876.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jubilant Pharmova Limited price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Jubilant Pharmova Limited. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Jubilant Pharmova Limited price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Jubilant Pharmova Limited Daily Moving Average Convergence/Divergence (MACD) ChartJubilant Pharmova Limited Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Jubilant Pharmova Limited. The current adx is 16.51.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Jubilant Pharmova Limited shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Jubilant Pharmova Limited Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Jubilant Pharmova Limited. The current sar is 589.60.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Jubilant Pharmova Limited Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Jubilant Pharmova Limited. The current rsi is 49.49. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Jubilant Pharmova Limited Daily Relative Strength Index (RSI) ChartJubilant Pharmova Limited Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Jubilant Pharmova Limited. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Jubilant Pharmova Limited price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Jubilant Pharmova Limited Daily Stochastic Oscillator ChartJubilant Pharmova Limited Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Jubilant Pharmova Limited. The current cci is -12.22340732.

Jubilant Pharmova Limited Daily Commodity Channel Index (CCI) ChartJubilant Pharmova Limited Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Jubilant Pharmova Limited. The current cmo is -0.35972534.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Jubilant Pharmova Limited Daily Chande Momentum Oscillator (CMO) ChartJubilant Pharmova Limited Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Jubilant Pharmova Limited. The current willr is -53.74001452.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Jubilant Pharmova Limited is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Jubilant Pharmova Limited Daily Williams %R ChartJubilant Pharmova Limited Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Jubilant Pharmova Limited.

Jubilant Pharmova Limited Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Jubilant Pharmova Limited. The current atr is 19.92.

Jubilant Pharmova Limited Daily Average True Range (ATR) ChartJubilant Pharmova Limited Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Jubilant Pharmova Limited. The current obv is 41,784,833.

Jubilant Pharmova Limited Daily On-Balance Volume (OBV) ChartJubilant Pharmova Limited Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Jubilant Pharmova Limited. The current mfi is 36.15.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Jubilant Pharmova Limited Daily Money Flow Index (MFI) ChartJubilant Pharmova Limited Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Jubilant Pharmova Limited.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-10DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-07MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-28CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Jubilant Pharmova Limited Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Jubilant Pharmova Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.492
Ma 20Greater thanMa 50570.910
Ma 50Greater thanMa 100573.982
Ma 100Greater thanMa 200531.027
OpenGreater thanClose572.150
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Jubilant Pharmova Limited with someone you think should read this too:
  • Are you bullish or bearish on Jubilant Pharmova Limited? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Jubilant Pharmova Limited? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Jubilant Pharmova Limited

I send you an email if I find something interesting about Jubilant Pharmova Limited.


Comments

How you think about this?

Leave a comment

Stay informed about Jubilant Pharmova Limited.

Receive notifications about Jubilant Pharmova Limited in your mailbox!